Nexavar Long Term Opportunities Are In Breast, Lung Cancer, Onyx CEO Renton Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A search is underway for a new CEO to take the helm of the drug maker after Renton’s planned retirement next year.
You may also be interested in...
Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
As Nexavar’s Oncology Potential Grows, So Do Bayer’s Sales Predictions
Firm says the kidney cancer drug’s additional indications in liver cancer and potentially other cancers will raise peak sales beyond €500 million.